Cervical cancer screening device company TruScreen will undertake a capital raise within the next year when market conditions begin to settle, its chair says.
The company's annual report, published yesterday, shows the auditors of the NZX and ASX-listed company had flagged that the 2022 financial
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
